Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Original Article

Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?

Clinical and Molecular Hepatology 2019;25(3):317-325.
Published online: June 10, 2019

1Department of Gastroenterology and Tropical Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt

2Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt

Corresponding author : Elham Ahmed Hassan Department of Gastroenterology and Tropical Medicine, Assiut University Hospital, Qesm Than Assiut, Al Walideyah Al Qebleyah, Assiut 71515, Egypt Tel: +20-882410285, Fax: +20-882333327 E-mail: mam_elham75@yahoo.com
• Received: November 22, 2018   • Revised: January 22, 2019   • Accepted: February 18, 2019

Copyright © 2019 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 15,349 Views
  • 132 Download
  • 4 Web of Science
  • 3 Crossref
  • 4 Scopus
prev next

Citations

Citations to this article as recorded by  Crossref logo
  • Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis
    Zhiyuan Hao, Yiting Lu, Yarong Hao, Yuanyuan Luo, Kaiming Wu, Changpeng Zhu, Peimei Shi, Feng Zhu, Yong Lin, Xin Zeng
    Journal of Gastroenterology.2025; 60(3): 340.     CrossRef
  • Mortality trends for cellulitis-related death in older adults in the United States: 24-year CDC analysis of gender, race, and geographical disparities
    Muhammad Shaheer Bin Faheem, Syeda Umbreen Munir, Mahnoor Javed, Syed Tawassul Hassan, Muhammad Bilal Masood, Kanz Ul Eman Maryam, Shamikha Cheema, Sumaya Samadi, Muhammad Idrees Khan
    Annals of Medicine & Surgery.2025; 87(12): 8471.     CrossRef
  • Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000–2015): A Nationwide Study
    Alejandro Alvaro-Meca, Irene Maté-Cano, Pablo Ryan, Verónica Briz, Salvador Resino
    Journal of Clinical Medicine.2020; 9(6): 1607.     CrossRef

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?
Clin Mol Hepatol. 2019;25(3):317-325.   Published online June 10, 2019
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?
Clin Mol Hepatol. 2019;25(3):317-325.   Published online June 10, 2019
Close
Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?
Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?
Compensated LC patients with cellulitis (n=25) Decompensated LC patients with cellulitis (n=52) LC patients with no cellulitis* (n=543) P-value
Age (years) 56.8±4.3 58.6±10.6 57.5±13.3 0.852
Sex (male/female) 15/10 (60/40) 33/19 (63.5/36.5) 336/207 (61.9/38.1) 0.827
Smoking 12 (48) 8 (15.4) 43 (7.9) 0.047
DM 6 (24) 14 (26.9) 206 (37.9) 0.490
Fever 13 (52) 32 (61.5) 277 (51) 0.259
Pain at the site of cellulitis 22 (88) 48 (92.3) - 0.773
Venous insufficiency 13 (52) 12 (23.1) 67 (12.3) 0.032
Trauma 5 (20) 6 (11.5) 51 (9.4) 0.439
No local risk detected 7 (28) 4 (7.7) - 0.041
Lower limb edema 0 39 (75) 294 (54.1) 0.002
Ascites 0 48 (92.3) 381 (70.2) 0.042
Site of cellulitis -
 Lower extremities 25 (100) 49 (92.2) 0.067
 Upper extremities 0 3 (5.8)
 Anterior abdominal wall 0 14 (26.2)
Gastrointestinal bleeding 0 4 (7.7) 65 (12) 0.492
Spontaneous bacterial peritonitis 0 11 (21.2) 98 (18) 0.556
Hepatic encephalopathy 0 19 (36.5) 207 (38.1) 0.287
Hepatocellular carcinoma 5 (20) 8 (15.4) 130 (23.9) 0.432
Serum albumin (g/dL) 3.7±0.4 2.1±0.5 2.6±0.7 0.002
Serum bilirubin (mg/dL) (median, range) 0.8 (0.4–1.3) 2.9 (0.2–22.2) 2.3 (0.3–23.2) 0.045
AST (U/L) (median, range) 21.5 (4–276) 61 (10–427) 52.5 (13–309) 0.864
ALT (U/L) (median, range) 38.5 (4–145) 34 (9–220) 32 (5–558) 0.563
INR 1.2±0.1 1.8±0.8 1.6±0.5 0.060
Serum creatinine (µmol/L) (median, range) 69.5 (55–93) 101 (38–559) 103.5 (22–627) 0.367
Serum sodium (mmol/L) 137±3.4 133±6 134±6.5 0.174
Leukocytic count (×109/L) 8.4±2.5 9.5±3.8 7.4±2.3 0.409
Hemoglobin (gm/dL) 10.4±1.8 10.1±2.2 9.1±2.4 0.770
Platelet count (×109/L) 138.5±42 109.7±50.2 132.1±78.7 0.161
MELD score 12±1.8 23±8.5 20.5±7.5 0.015
MELD-Na score 12.8±2.8 28.6±12.9 25.3±10.2 0.049
Local complications -
 Abscesses 2 (8) 7 (12.5) 0.651
 Gangrene 1 (4) 5 (9.6)
 Hemorrhagic bullae 0 1 (1.9)
Recurrence 1 (4) 7 (12.5) - 0.510
Septic shock 0 6 (11.5) - 0.597
In-hospital mortality 0 21 (40.4) 184 (33.9) 0.354
Organisms Compensated cirrhosis Decompensated cirrhosis
Gram positive bacteria (skin/blood culture)
Streptococcus pyogenes 3 (2/1) 2 (0/2)
Staphylococcus species 4 (3/1) 10 (4/6)
  MRCNS 1 (1/0) 1 (0/1)
  MSSA - 2 (1/1)
  MRSA 2 (1/1) 5 (2/3)
  Staphylococcus coagulase - 1 (1/0)
  Staphylococcus hominis 1 (1/0) 1(0/1)
Gram negative bacteria (skin/blood culture)
Escherichia coli 0 11 (2/9)
Klebsiella pneumoniae 0 10 (3/7)
Pseudomonas aeruginosa 0 3 (0/3)
Fungi (skin/blood culture)
Candida albicans 0 1 (1/0)
Aspergillus niger 0 2 (0/2)
No. Age Sex Cellulitis Host factors CP MELD Skin/Blood culture Treatment
1 82/F Recurrent bilateral LL cellulitis: severe, not oozing DM, fever, HE, septic shock 11 28 E. coli/P. aeruginosa Empirical
2 78/F Bilateral LL cellulitis: severe, not oozing HE, intractable ascites 11 25 -/K. pneumoniae Empirical
3 65/M Bilateral LL cellulitis: pyogenic, severe, oozing DM, HTN, fever, HRS 8 27 Staph. coagulase/E. coli Empirical
4 57/M Left LL cellulitis: severe, not oozing. echymosis, bullae below big toe HE, fever, septic shock 13 29 -/P. aeruginosa, E. coli Empirical then adjusted
5 55/M Anterior abdominal wall: severe, oozing, ulceration, abscess DM, intractable ascites, SBP 13 20 -/MRCNS, K. pneumoniae Empirical
6 55/M Recurrent right LL cellulitis: severe, not oozing HCC, HRS, intractable ascites 15 42 K. pneumoniae/MRSA, E. coli Empirical
7 55/F Anterior abdominal wall: severe, oozing. gangrene DM, HTN, HE 9 21 E. coli/K. pneumoniae Empirical then adjusted
8 55/F Left LL cellulitis: severe, oozing, gangrene DM, HCC, fever, septic shock 11 31 MRSA, K. pneumoniae/E. coli Empirical
9 52/F Recurrent bilateral LL cellulitis: severe, not oozing Fever, HRS, HE 14 40 -/K. pneumoniae Empirical
10 45/M Anterior abdominal wall: severe, oozing, abscess Intractable ascites, SBP, septic shock 14 29 -/Strept. pyogenes, P. aeruginosa Empirical then adjusted
11 44/M Right LL cellulitis: severe, oozing Intractable ascites, HRS 10 22 K. pneumoniae/- Empirical
Survivors (n=56) Non-survivors (n=21) P-value
Age (years) 58.9±10 57.4±11.4 0.605
Sex (male/female) 35/21 (62.5/37.5) 13/8 (61.9/38.1) 0.910
Smoking 15 (26.8) 5 (23.8) 0.633
Diabetes mellitus 16 (28.6) 4 (19) 0.542
Hospital stay (days) (median, range) 7 (3–20) 13 (2–25) 0.029
Fever 34 (60.7) 11 (52.4) 0.718
Pain at the site of cellulitis 51 (91.1) 19 (99.5) 0.859
Traumatic wounds 8 (14.3) 3 (14.3) 0.508
Venous insufficiency 18 (32.1) 7 (33.3) 0.901
LL edema 21 (37.5) 18 (85.7) 0.037
Ascites 32 (57.1) 16 (76.2) 0.155
Site of cellulitis* (UL/LL/anterior abdominal wall) 3/55/9 (5.4/98.2/16.1) 0/19/5 (0/90.5/23.8) 0.422
Gastrointestinal tract bleeding 4 (7.1) 0 0.201
Spontaneous bacterial peritonitis 7 (12.5) 4 (19) 0.678
Hepatic encephalopathy 12 (21.4) 7 (33.3) 0.276
Hepatocellular carcinoma 8 (14.3) 5 (23.8) 0.231
Complicated cellulitis 7 (12.5) 9 (42.9) <0.001
Septic shock 0 6 (28.6) 0.023
Recurrent cellulitis 2 (3.6) 6 (28.6) 0.025
Treatment (empirical/empirical then adjusted) 42/14 (75/25) 16/5 (76.2/23.8) 0.780
Serum albumin (g/dL) 21.1±5.2 21.6±4.2 0.733
Serum bilirubin (mg/dL) (median, range) 2.5 (0.4–14.4) 3.4 (0.2–22.2) 0.101
INR 1.6±0.4 2.3±0.3 0.034
Serum creatinine (µmol/L) (median, range) 87 (42–347) 176 (38–559) 0.047
Serum sodium (mmol/L) 133.4±5.3 130.2±7.1 0.046
Leukocytic count (×109/L) 8.1±3.8 13±5.8 0.067
Child-Pugh score 10±2 11.3±2.4 0.031
MELD score 19.8±7 28.9±9.4 <0.001
MELD-Na score 22.9±9.2 38.2±10.5 <0.001
Odds ratio (95% CI) P-value
Hospital stay (days) 1.27 (1.07–1.49) 0.005
Lower limb edema 1.77 (0.29–10.41) 0.537
Locally complicated cellulitis 21.56 (3.31–40.42) 0.001
Recurrent cellulitis 17.35 (2.60–25.71) 0.003
Septic shock 5.41 (0.88–33.36) 0.032
Child-Pugh score 0.66 (0.36–1.22) 0.185
MELD-Na score 1.33 (1.12–1.58) 0.001
Table 1. Characteristics and risk factors of cellulitis in patients with hepatitis C virus-related cirrhosis (compensated and decompensated)

Values are presented as mean±standard deviation or n (%) unless otherwise indicated. P -value <0.05 means significant.

LC, liver cirrhosis; DM, diabetes mellitus; AST, aspartate transaminase; ALT, alanine transaminase; INR, international normalized ratio; MELD, model for endstage liver disease.

No cellulitis group included compensated and decompensated cirrhotic patients without cellulitis.

More than one area of cellulitis was seen in seven cases (leg and anterior abdominal wall cellulitis).

Venous insufficiency was diagnosed by doppler ultrasonography.

Table 2. Frequency of microorganisms in 23 cirrhotic patients with cellulitis (in skin and blood cultures)

MRCNS, methicillin-resistant coagulase-negative Staphylococci; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus.

Table 3. Detailed characteristics of bacteriologically-proven cellulitis in deceased cirrhotic patients

CP, Child–Pugh classification; MELD, model for end-stage liver disease; F, female; LL, lower limb; DM, diabetes mellitus; HE, hepatic encephalopathy; E. coli, Escherichia coli; P ., Pseudomonas; K. , Klebsiella; M, male; HTN, hypertension; HRS, hepatorenal syndrome; Staph. , Staphylococcus; SBP, spontaneous bacterial peritonitis; MRCNS, methicillin-resistant coagulase-negative staphylococci; HCC, hepatocellular carcinoma; MRSA, methicillin-resistant Staphylococcus aureus; Strept., Streptococcus.

Table 4. Demographic and clinical characteristics of cirrhotic patients with cellulitis (survivors and non-survivors)

Values are presented as mean±standard deviation or n (%) unless otherwise indicated. P-value <0.05 means significant.

UL, upper limb; LL, lower limb; INR, international normalized ratio; MELD, model for end-stage liver disease.

More than one area of cellulitis was seen in seven cases (leg and anterior abdominal wall cellulitis).

Table 5. Predictors of in-hospital mortality in cirrhotic patients with cellulitis

P-value<0.05 means significant.

CI, confidence interval; MELD, model for end-stage liver disease.